NAPWA

Search

Enter your keywords:

Advanced search

Containing any of the words:

Containing the phrase:

Containing none of the words:

Only in the category(s): publicANET resourcesconference reportsCurrent issuesfact sheets-ATPA fact sheetsjob vacanciesmedia releasesNAPWA newsnews-HIV sector news-international news-national news-news briefs-treatments newsQ&Areports and submissions-conference presentations-discussion papers-submissionsStories from Positive Living-regular features--Backgrounder--Complementary Therapies (column)--Positive Voices--What's Your Problem?-by issue date--2003---Feb-Mar 2003---Apr-May 2003---Jun-Jul 2003---Aug-Sep 2003---Oct-Nov 2003---Dec 2003-Jan 2004--2004---Dec 2004-Jan 2005---Feb-Mar 2004---Apr-Jun 2004---Aug-Sep 2004---Oct-Nov 2004--2005---Feb-Mar 2005---Apr-May 2005---Jun-Jul 2005---Aug-Sep 2005---Oct-Nov 2005---Dec 2005-Jan 2006--2006---Oct 2006---Dec 2006--2007---July 2007---March 2007Chin WagNational Treatments RoadshowNewly diagnosed-HIV/AIDS basicsLiving with HIV-children and young people-grief and loss-heterosexuals-personal stories-pregnancy and childbirth-preventing transmission--positive in prevention--preventative vaccines--sex---disclosure---microbicides---negotiation---PEP---PrEP---safe sex--superinfection/reinfection-recreational drugs-relationships-sex work-social research--HIV Futures-stigma-travel and immigration--immigration--travelling with HIVStaying well-basic science-exercise-HIV treatments--adherance---drug holidays--attachment inhibitors---873140---maraviroc---SCH532706---TAK-652---TNX-355---vicriviroc--clinical trials--complementary and alternative therapies---medical cannabis--drug interactions---drug resistance--entry inhibitors---PRO-542---T-20--experimental treatments---brecanavir---darunavir (TMC-114)---elvitegravir (GS-9137)---etravirine (TMC-125)---PA-457---raltegravir (MK-0518)---rilpivirine (TMC 278)---tipranavir--immune-based therapies---IL-2---therapeutic vaccines--integrase inhibitors--maturation inhibitors--multi-class formulations---Truvada--NNRTIs---delavirdine---efavirenz---nevirapine--NRTIs---3TC---abacavir---AZT---Combivir---d4T---ddC---ddI---Epzicom---FTC---Trizivir--NtRTIs---tenofovir--prophylaxis--protease inhibitors---(fos)amprenavir---atazanavir---indinavir---lopinavir---nelfinavir---ritonavir---saquinavir--salvage therapy--Special Assistance Schemes--starting treatments--strategic treatment interruption-nutrition-oral health--gingivitus/periodontal disease-smoking-symptoms, illnesses and opportunistic infections--CMV--cryptococcal meningitis--diabetes--diarrhoea--fatigue--heart disease--hepatitis A--hepatitis B--hepatitis C--lipodystrophy---polylactic acid---rosiglitazone---uridine--mental health---stress, depression, anxiety--mitochondrial toxicity--neurological conditions---dementia---PML--opportunistic infections--pancreatitis--peripheral neuropathy--sexual dysfunction--sexually-transmissible infections---chlamydia---genital herpes---gonorrhoea---HPV---syphilis--shingles--thrush--toxoplasmosis--treatment side effects-tests--CD4 counts--HIV tests--resistance tests--therapeutic drug monitoring (TDM)--viral loadGetting support-income support--Disability Support Pension---Centrelink reviews--superannuation-insurance--life insurance--private health insurance--travel insurance-Medicare-Pharmaceutical Benefits Scheme-work and employment--returning to work--stopping workOur rights-discrimination-human rights-privacyPositive womenIndigenous peopleGlobal HIV/AIDS-art and culture--book reviews--the media-HIV in our region-HIV/AIDS sector-involvement of positive people-national AIDS strategy-The Global Fund-World AIDS DayHIV research-clinical research-pathogenesisNational Portfolios & Networks-Education Portfolio-Health+Treatments Portfolio-HIV Living Today Network-Regional NetworkNational Networks-PATSIN-Positive Women's NetworkProjects-HIV Health Project-HIV Living Project/Regional Unit--AHAPI ProjectAIDS Treatment Project AustraliaNAPWA Conference-2001 Conference-2003 Conference-2005 ConferenceCover storyNewsFeatureRegularAustralia-Australian Capital Territory--Canberra-New South Wales--Sydney-Northern Territory--Darwin-Queensland--Brisbane--Cairns-rural and remote Australia-South Australia--Adelaide-Tasmania--Hobart-Victoria--Melbourne-Western Australia--PerthInternational-Africa--South Africa-Asia--Cambodia--India--Indonesia--Laos--Thailand-Europe-North America--United States-Pacific--Fiji--New Zealand--Papua New Guinea-South America--BrazilACFIDadverse eventAFAOAFAPAHAPIAHRNALTanaemiaanginaantiretroviralantiviralAPCASOAPN+APNSWAPPRCARCARCSHSarmarteryASAPASHMaspergillosisatherosclerosisatypical pneumoniaAusAIDB cellsbacteriumbaselinebiasbilirubinbilirubinbioavailabilitybiopsyblindblipblood-brain barrierCARAMcarbohydratecardiomyopathycholesterolclinicalclinical investigatorclinical trialcohortcomplementary therapycontraindicationcontrol groupcontrolled trialcoronary arterycoronavirusData Safety and Monitoring Boarddentinediabetesdiagnostic trialdose-rangingdouble-blinddrug classdrug-drug interactionefficacyempiricalenamelendpointenrolmentepidemiologyethicsexclusion criteriaexperimentalFood and Drug AdministrationgenegingivitisGNP+HAARTHBVHCVhepatitisHIV groupHIV-1HIV-2hypertensionhypothesisICAAPIgat HopeIGCAHRDin vitroinclusion criteriainfluenzainformed consentinformed consent documentinsulin resistanceintent-to-treatIPN+ISAITPClipidlipodystrophyliverMACASHHmyocardial infarctnatural history studyNCHECRNCHSRNGONHASPnucleoside analogueoff-labelopen labelPATSINPBSpeer reviewperiodontal diseasepHpharmacokineticPhase IPhase IIPhase IIIPhase IVplaceboplacebo controlledplacebo effectplaquePLWHApneumoniaPNGpreclinicalprevention trialprotease inhibitorprotocolquality of life trialrandomisedrandomised trialresistancereverse transcriptase inhibitorribavirinsalvageSARSset pointside effectSpecial Access SchemesteroidSTIstrainsubtypeTGAtriglycerideUNAIDSviral loadvirus

Only of the type(s):

Advertisement

Book page

Discussion

Event

Event template

Group

HIV organisation

Image

Media Release

Page

Positive Living article

Positive Living issue

Story

Treatment info

Webform

• Living with HIV
• Newly diagnosed?
• Current issues
• Living with HIV
• Staying well
• Getting support
• Our rights
• Positive women
• Indigenous people
• Global HIV
• Services in your area

• Our organisations
• About NAPWA
• NAPWA portfolios
• NAPWA Conference
• About the ATPA

• Our publications
• Positive Living
• Fact sheets
• Reports/submissions
• Email lists

• Media releases
• Calendar
• Links
• Contact NAPWA
• About this site

• Text size: A A A
• Glossary
• RSS feeds

Search
this site selected websites

PO Box 917, Newtown NSW 2042 • Telephone (02) 8568 0300 • Freecall 1800 259 666 • Fax (02) 9565 4860 • Full contact details